FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review. PMID 36213836 · J Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 3 Panel · risk visible |
| Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. PMID 36212393 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. PMID 36172173 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 1 Figure · 4 Panel · risk not_visible |
| Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. PMID 36160459 · Front Pharmacol · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective. PMID 36155490 · Keio J Med · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer. PMID 36148376 · Adv Radiat Oncol · 2022 Study is a retrospective single-arm analysis of outcomes after SABR, not a randomized trial and does not involve a drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation. PMID 36132135 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Patterns of failure and long-term outcome of postoperative radiotherapy on the survival of patients with pathological T3N0M0 esophageal cancer. PMID 36117831 · Front Surg · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial. PMID 36092918 · Front Genet · 2022 The record is from a randomized Phase 3 trial in oncology (human, glioblastoma) and is an original report with results. However, the abstract does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) for the drug intervention (temozolomide). The analysis focuses on methylation profiling as a prognostic marker for survival subgroups within the trial, not on the efficacy of the drug itself. Therefore, it does not meet the requirement for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. PMID 36091159 · Front Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. PMID 36032351 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. PMID 36003374 · Front Immunol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. PMID 35983099 · Front Med (Lausanne) · 2022 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study). PMID 35983025 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. PMID 35983024 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 4 Panel · risk visible |
| Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial. PMID 35929135 · Technol Cancer Res Treat · 2022 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial? PMID 35923929 · Ther Adv Med Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Characteristics and trends of globally registered glioma clinical trials in the past 16 years. PMID 35923217 · Ther Adv Neurol Disord · 2022 The record is a cross-sectional landscape analysis of registered glioma trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial. It does not present original, formal results (including time-to-event endpoints like OS or PFS) for a specific drug-containing intervention. Therefore, it is excluded. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. PMID 35912196 · Front Oncol · 2022 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis. PMID 35909569 · Front Endocrinol (Lausanne) · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. PMID 35856081 · Commun Med (Lond) · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. PMID 35847009 · Front Pharmacol · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer. PMID 35812062 · Am J Cancer Res · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. PMID 35774122 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. PMID 35769948 · Oncoimmunology · 2022 The record is a preclinical/experimental journal article that discusses and interprets two published phase III clinical trials. It is not an original formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The deterministic review signal 'no_time_to_event_signal' is correct for this record as a potential source of trial data. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50. PMID 35747163 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 2 Figure · 4 Panel · risk unclear |
| Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials. PMID 35724627 · Cancer Treat Res Commun · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. PMID 35721168 · Front Pharmacol · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. PMID 35720069 · Front Neurol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial. PMID 35702414 · Ecancermedicalscience · 2022 This is a sub-analysis of trial activation timelines, not a report of the trial's primary or secondary efficacy results with time-to-event outcomes. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy. PMID 35692538 · Front Med (Lausanne) · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PMID 35646119 · J Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis. PMID 35619813 · Front Public Health · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. PMID 35574391 · Front Oncol · 2022 This is a single-arm, non-randomized pilot study, not a randomized Phase III/IIIb or Phase II/III trial. It is therefore ineligible. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial. PMID 35547106 · Rare Tumors · 2022 The report is an original quality-of-life analysis from a phase III randomized oncology trial. It meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because its primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR-based analysis). The report type is 'quality_of_life', which is an excluded category. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. PMID 35515356 · Breast Cancer (Dove Med Press) · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China. PMID 35515123 · Front Oncol · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. PMID 35506019 · Lung Cancer (Auckl) · 2022 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs. PMID 35494084 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. PMID 35494078 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. PMID 35433482 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). PMID 35433421 · Front Oncol · 2022 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Frontline therapy for advanced hepatocellular carcinoma: an update. PMID 35432597 · Ther Adv Gastroenterol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib. PMID 35356064 · Dis Markers · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 8 Panel · risk visible |
| A narrative review of postoperative adjuvant radiotherapy for non-small cell lung cancer. PMID 35340837 · Mediastinum · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. PMID 35309087 · Ther Adv Med Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy. PMID 35283642 · Cancer Manag Res · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 2 Panel · risk visible |
| Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial. PMID 35251955 · Front Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 9 Panel · risk visible |
| Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. PMID 35251319 · Ther Adv Med Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PMID 35155246 · Front Oncol · 2022 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |